14 November 2018
Visiongain has launched a new pharma report: Biologics Market Trends : Protein Therapeutics, Monoclonal Antibodies, Fusion Proteins, Regenerative Medicines, Insulin, Other Recombinant Hormones, Plasma & Recombinant Coagulating Factors, Interferons, Enzyme Replacement, Stem Cell Therapies, Tissue Engineered Products, Gene Therapies
Bio therapeutics is the fastest-growing sector in the pharmaceutical industry, with total revenues reaching up to $163 billion. Its annual growth surpasses 8%, whereas conventional pharmaceuticals barely reach 4%. The current landscape of biologics promises continuous growth. Biologics are much costlier than small molecule drugs, these classes of drugs bring about 40% higher profit to the manufacturers when compared to small molecule drugs. Additionally, the growing demand for biologics drugs coupled with the increased regulatory approvals for these drugs will increase the demand for biologics manufacturing and testing at various levels of clinical studies as well as commercial supply.
The lead analyst of the report commented "The biologics market is built on technological innovation and continued development of biotechnology is the key to the market’s future. The tools for innovation as well as for manufacturing are becoming widely disseminated. The suite of techniques that stand behind the current mAbs market, including phage display, humanisation and transgenic mice, are now off-patent and available to any company that wishes to take advantage of them.
Therefore, there is a major need for new platforms that can keep new and emerging technologies in the hands of innovator companies. Rapid advances in assays will also have a major knock-on effect on the biopharmaceutical industry, both by permitting more rapid and accurate characterisation of biologics and biosimilars, and by allowing new diagnostic tools into the market. New diagnostics will accelerate the rise of personalised medicine, which is likely to be highly relevant to the future of the biologics market."
Leading companies featured in the report include AbbVie, Amgen, AstraZeneca, Bayer, Eli Lilly, Roche, GlaxoSmithKline (GSK), Johnson & Johnson, Merck & Co., Inc., Novartis, Pfizer, Sanofi S.A.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The pharma wholesale and distribution market was valued at US$511.80 billion in 2021 and is projected to grow at a CAGR of 7.84% during the forecast period 2022-2032.
29 September 2022
The mesenchymal stem cells market was valued at US$2.44 billion in 2021 and is projected to grow at a CAGR of 13.82% during the forecast period 2022-2032.
21 September 2022
The global advanced wound care management market is estimated to be valued at US$12,581.3 million in 2022. The market is projected to reach a market value of US$23,307.5 million by 2032 and is projected to grow at a CAGR of 6.36% during the forecast period 2022-2032.
16 September 2022
The gene therapy R&D market was valued at US$1,653.0 million in 2021 and is projected to grow at a CAGR of 30.1% during the forecast period 2022-2032.